Budesonide (BUD) Market Size, Share, Growth, and Industry Analysis, By Type (Nasal Spray, Inhaler, Pill), By Application (Respiratory Disease Treatment, Nose Disease Treatment, Inflammatory Bowel Disease Treatment), Regional Forecast To 2031

BUDESONIDE (BUD) MARKET REPORT OVERVIEW

• 

•  Request a Free Sample to learn more about this report

global budesonide (bud) market size was USD 8203 million in 2021 and market is projected to touch 11200.22 million by 2031, exhibiting a CAGR of 3.1% during the forecast period.

Budesonide (BUD) is a corticosteroid medication that is used to treat a variety of respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. It is a type of inhaled corticosteroid, which means that it is delivered directly to the lungs.

Budesonide (BUD) works by reducing inflammation in the airways. This makes it easier to breathe and can help to prevent asthma attacks and COPD exacerbations. Budesonide is also used to treat nasal polyps, which are non-cancerous growths in the nose. Budesonide is available in a variety of forms, including inhalers, nebulizers, and nasal sprays. It is usually taken once or twice a day.

COVID-19 Impact: Pandemic Decreased the Market Demand

The COVID-19 pandemic has had a significant impact on the budesonide (BUD) market share. The COVID-19 pandemic has led to an increase in respiratory diseases, including asthma and COPD. This has led to an increased demand for budesonide (BUD), which is a corticosteroid used to treat these diseases. In fact, a study by the Global Asthma Network found that the number of people with asthma increased by 10% during the first year of the pandemic. There are a number of reasons why the COVID-19 pandemic has led to an increase in respiratory diseases. One reason is that the virus can cause inflammation in the airways, which can trigger asthma attacks or COPD exacerbations. Another reason is that the pandemic has led to people spending more time indoors, which can increase exposure to allergens and pollutants that can trigger respiratory problems. The increased demand for budesonide (BUD) has led to higher prices for the drug. In some cases, there have also been shortages of budesonide. This is because the pandemic has disrupted the supply chain for budesonide, making it more difficult for manufacturers to produce the drug.

Latest Trends

"The increasing use of budesonide for the treatment of chronic obstructive pulmonary disease (COPD) is expected to fuel the growth in the market"

COPD is a chronic lung disease that is caused by a combination of smoking and environmental factors. The disease causes inflammation and damage to the airways, which makes it difficult to breathe. COPD is the third leading cause of death in the world, and it is estimated that there are over 300 million people living with the disease. Budesonide (BUD) is a corticosteroid that is used to treat a variety of respiratory diseases, including asthma and COPD. Budesonide works by reducing inflammation in the airways, which makes it easier to breathe. Budesonide is a safe and effective treatment for COPD, and it has been shown to improve lung function and reduce the risk of exacerbations. The development of new budesonide (BUD) formulations has made it easier for people with COPD to use the drug. For example, AstraZeneca has developed a budesonide/formoterol inhaler that is designed to provide long-lasting relief from COPD symptoms.

BUDESONIDE (BUD) MARKET SEGMENTATION

• 

•  Request a Free Sample to learn more about this report

• By Type Analysis

According to type, the market can be segmented nasal spray, inhaler, pill.

• By Application Analysis

Based on application, the market can be divided into respiratory disease treatment, nose disease treatment, inflammatory bowel disease treatment.

Driving Factors

"Increasing prevalence of asthma and COP to foster the market growth"

Asthma and COPD are two of the most common respiratory diseases in the world. Asthma is a chronic condition that causes inflammation of the airways, making it difficult to breathe. COPD is a chronic lung disease that causes shortness of breath, coughing, and wheezing. The prevalence of asthma and COPD is increasing worldwide. This is due to a number of factors. Air pollution, cigarette smoke, and other environmental factors can increase the risk of developing asthma and COPD. Some people are more likely to develop asthma and COPD due to their genes. Obesity, smoking, and a sedentary lifestyle can also increase the risk of developing asthma and COPD. The increasing prevalence of asthma and COPD is driving the budesonide market. Budesonide (BUD) is a safe and effective treatment for both asthma and COPD. As the number of people with these diseases increases, the demand for budesonide is also increasing.

"Growing awareness of the benefits of budesonide to result in the expansion of the market"

In addition to the increasing prevalence of asthma and COPD, the growing awareness of the benefits of budesonide is also driving the budesonide market. Budesonide is a corticosteroid, which means that it works by reducing inflammation in the airways. This makes it easier to breathe and can help to prevent asthma attacks and COPD exacerbations. In recent years, there has been a growing awareness of the benefits of budesonide (BUD) among healthcare professionals and patients. This has led to an increase in the use of budesonide for the treatment of asthma and COPD. The combination of the increasing prevalence of asthma and COPD and the growing awareness of the benefits of budesonide is driving the budesonide market.

Restraining Factors

"The potential side effects to hamper the market growth"

The potential side effects of budesonide can hamper the budesonide market in a number of ways. For example, patients who are concerned about the potential side effects of budesonide may be less likely to use the drug. This could lead to a decrease in demand for budesonide.

BUDESONIDE (BUD) MARKET REGIONAL INSIGHTS

• 

•  Request a Free Sample to learn more about this report

"Asia Pacific to lead the market owing to increasing prevalence of asthma and COPD. "

The Asia Pacific region has shown the highest budesonide (BUD) market growth. The increasing prevalence of asthma and COPD in the region. According to the World Health Organization, asthma is the most common chronic disease among children in the Asia Pacific region, and COPD is the fourth leading cause of death. The growing awareness of the benefits of budesonide. Budesonide is a safe and effective treatment for asthma and COPD, and there is a growing awareness of this among healthcare professionals and patients in the region.

Key Industry Players

"Key players are employing advanced technologies in order to stimulate further growth of the market"

All the major players are motivated to offer superior and more advanced services in order to gain a competitive edge in the market. To increase their market presence, vendors are using a variety of techniques, including product launches, regional growth, strategic alliances, partnerships, mergers, and acquisitions.

LIST OF TOP BUDESONIDE (BUD) COMPANIES

• AstraZeneca: Cambridge, UK
• Cosmo Pharmaceuticals: Saronno, Italy
• Teva Pharmaceutical Industries: Petach Tikva, Israel
• Mylan: Canonsburg, Pennsylvania, USA
• Sandoz: Holzkirchen, Germany
• Dr. Falk Pharma: Freiburg, Germany
• Chiesi Farmaceutici: Parma, Italy
• Orion: Espoo, Finland
• Cipla: Mumbai, India
• Synmosa Biopharma: Singapore
• Lunan Better Pharmaceutical: Changzhou, China
• Shanghai Sine Promod Pharmaceutical: Shanghai, China

Report Coverage

This report examines an understanding of the budesonide (BUD) market’s size, share, growth rate, segmentation by type, application, key players, and previous and current market scenarios. The report also collects the market’s precise data and forecasts by market experts. Also, it describes the study of this industry’s financial performance, investments, growth, innovation marks, and new product launches by the top companies and offers deep insights into the current market structure, competitive analysis based on key players, key driving forces, and restraints that affect the demand for growth, opportunities, and risks.

Furthermore, the post-COVID-19 pandemic’s effects on international market restrictions and a deep understanding of how the industry will recover, and strategies are also stated in the report. The competitive landscape has also been examined in detail to provide clarification of the competitive landscape.

This report also discloses the research based on methodologies that define price trend analysis of target companies, collection of data, statistics, target competitors, import-export, information, and previous years’ records based on market sales. Moreover, all the significant factors which influence the market such as small or medium business industry, macro-economic indicators, value chain analysis, and demand-side dynamics, with all the major business players have been explained in detail. This analysis is subject to modification if the key players and feasible analysis of market dynamics change.